These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 35865399)

  • 1. Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria.
    Schiaroli E; De Socio GV; Gidari A; Malincarne L; Benedetti S; Lanzi A; Bastianelli S; Pierucci S; Busti C; Fagotti B; Vicenti I; Zazzi M; Francisci D
    Mediterr J Hematol Infect Dis; 2022; 14(1):e2022050. PubMed ID: 35865399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern.
    Falcone M; Tiseo G; Valoriani B; Barbieri C; Occhineri S; Mazzetti P; Vatteroni ML; Suardi LR; Riccardi N; Pistello M; Tacconi D; Menichetti F
    Infect Dis Ther; 2021 Dec; 10(4):2479-2488. PubMed ID: 34435337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19.
    Mazzotta V; Cozzi-Lepri A; Colavita F; Lanini S; Rosati S; Lalle E; Mastrorosa I; Cimaglia C; Vergori A; Bevilacqua N; Lapa D; Mariano A; Bettini A; Agrati C; Piselli P; Girardi E; Castilletti C; Garbuglia AR; Vaia F; Nicastri E; Antinori A
    Front Immunol; 2022; 13():868020. PubMed ID: 35514955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Agrawal P; Damania D; Cseh A; Grab J; Strom L; Frank B; Patel D; Clyatt G
    Vaccine; 2023 Aug; 41(35):5195-5200. PubMed ID: 37451874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.
    Bierle DM; Ganesh R; Razonable RR
    J Clin Virol; 2021 Dec; 145():105026. PubMed ID: 34775142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.
    Keshishian E; Kuge E; Memmott J; Hasenbalg P; Belford N; Matlock A; Schritter S; Agbayani G; Dietrich T; Santarelli A; Ashurst J
    J Osteopath Med; 2022 Dec; 122(12):635-640. PubMed ID: 36123325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.
    Arimura K; Tagaya E; Kikuchi K; Mitsuda T; Ebihara F; Maruyama T; Hamada Y; Unagami K; Kanzawa T; Sekiguchi H; Shimamoto K; Ishida H; Egawa H; Tanaka J; Kawana M
    Transpl Immunol; 2023 Apr; 77():101777. PubMed ID: 36584927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
    Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
    J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant.
    Cicchitto G; Cardillo L; de Martinis C; Sabatini P; Marchitiello R; Abate G; Rovetti A; Cavallera A; Apuzzo C; Ferrigno F; Fusco G
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab.
    Heller M; Henrici C; Büttner J; Leube S; Treske I; Pospischil P; Doll M; Schanz I; Hallier A; Herrmann E; Schmidt M; Sarrazin C
    Int J Infect Dis; 2023 Apr; 129():260-265. PubMed ID: 36690138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
    Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
    Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review.
    Ravi G; Eerike M; Konda VR; Bisoi D; Raj GM; Priyadarshini R; Mali KR; Chaliserry LF
    Monoclon Antib Immunodiagn Immunother; 2023 Apr; 42(2):77-94. PubMed ID: 37129306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1-August 20, 2021): a retrospective observational monocentric study.
    Guo Y; Cowman K; Chang M; Bao H; Golia A; Mcsweeney T; Bard L; Simpson R; Andrews E; Pirofski LA; Nori P
    BMC Infect Dis; 2022 Jul; 22(1):645. PubMed ID: 35896965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.
    Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Ishii T; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Kanbe T; Kanzaki N; Azuma T; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Tsukada Y; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Umeda T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Iseki K
    Int J Med Sci; 2022; 19(5):834-841. PubMed ID: 35693744
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
    Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies.
    Vellas C; Del Bello A; Gaube G; Tremeaux P; Jeanne N; Ranger N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac093. PubMed ID: 35299988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis.
    San Filippo S; Crovetto B; Bucek J; Nahass RG; Milano M; Brunetti L
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac080. PubMed ID: 35299987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series.
    Fernandes G; Devresse A; Scohy A; De Greef J; Yombi JC; Belkhir L; Darius T; Mourad M; Buemi A; Kabamba B; Goffin E; Kanaan N
    Kidney Med; 2022 Jun; 4(6):100470. PubMed ID: 35493029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.